

COLORECTAL CANCER (CRC) BIOMARKERS AND TREATMENT IMPACT

BIOMARKER	WHO SHOULD BE TESTED?	WHAT IS IT?	WHAT IS THE TREATMENT IMPACT?	
MSS	<ul style="list-style-type: none"> All colorectal cancer (bowel cancer) patients 	<ul style="list-style-type: none"> MSS is microsatellite stability MSS and MSI-High are assessments of your cells' ability to fix certain kinds of genetic mistakes. 	<ul style="list-style-type: none"> CRC with MSS is treated with traditional chemotherapy. CRC with MSS and TMB-High can be treated with immunotherapy. 	
MSI-HIGH	<ul style="list-style-type: none"> All colorectal cancer patients All patients with MSI-High results should also be tested for the hereditary Lynch Syndrome 	<ul style="list-style-type: none"> MSI-High is microsatellite instability-high (also known as deficient mismatch repair, dMMR). MSS and MSI-High are assessments of your cells' ability to fix certain kinds of genetic mistakes. 	<ul style="list-style-type: none"> Immunotherapy is effective in MSI-High colorectal cancer. 	
KRAS	<ul style="list-style-type: none"> All stage IV / metastatic CRC patients All patients being considered for EGFR inhibitor treatment 	KRAS is a gene involved in controlling cell growth and cell survival. Mutations in KRAS may allow cells to grow out of control and become cancer.	CRC without KRAS mutation (wild-type) is treated with EGFR inhibitors.	<ul style="list-style-type: none"> Colorectal cancer with KRAS mutation is treated with traditional chemotherapy with or without bevacizumab added. EGFR inhibitors are not effective in tumors (tumours) with KRAS mutation.
NRAS	<ul style="list-style-type: none"> All stage IV / metastatic CRC patients All patients being considered for EGFR inhibitor treatment 	NRAS is a gene involved in controlling cell growth and cell survival. Mutations in NRAS may allow cells to grow out of control and become cancer.	CRC without NRAS mutation (wild-type) is treated with EGFR inhibitors.	<ul style="list-style-type: none"> Colorectal cancer with NRAS mutation is treated with traditional chemotherapy with or without bevacizumab added. EGFR inhibitors are not effective in tumors with NRAS mutation.
HER2 (ERBB2)	All stage IV / metastatic CRC patients, unless a KRAS, NRAS, or BRAF mutation has already been identified	HER2 is a gene involved in control of cell growth and cell survival. An increased number of HER2 gene copies (amplification) and increased amount of HER2 protein (overexpression) can cause cancer by allowing abnormal control of cell growth and survival.	HER2 negative tumors are treated based on other patient and biomarker information.	<ul style="list-style-type: none"> CRC that is HER2 positive (has HER2 amplification or overexpression) may be treated with HER2 inhibitors with or without traditional chemotherapy. EGFR inhibitors are less effective in colorectal cancer with HER2 amplification.
BRAF (INCLUDING BRAF V600E)	All stage IV / metastatic CRC patients	BRAF is a gene involved in controlling cell growth. Mutations in BRAF may allow cells to grow out of control and become cancer.	Tumors without BRAF mutation (wild-type) are typically treated with EGFR inhibitors.	<ul style="list-style-type: none"> CRC with BRAF mutation is treated with targeted therapy (BRAF inhibitors plus MEK inhibitors) with or without traditional chemotherapy. EGFR inhibitors alone are not effective in BRAF mutant tumors but may be added to other targeted therapy.
CEA	All CRC patients	CEA is carcinoembryonic antigen, a substance produced by colorectal cancer cells and by intestinal cells in some other benign diseases.	A decreasing CEA level during treatment is a sign that the treatment is effective.	<ul style="list-style-type: none"> An increasing CEA level over time may indicate cancer progression on treatment or a return of cancer after treatment. Further testing is needed to confirm progression or recurrence.

BIOMARKER	WHO SHOULD BE TESTED?	WHAT IS IT?	WHAT IS THE TREATMENT IMPACT?	
TUMOR LOCATION (TUMOR SIDEDNESS)	<ul style="list-style-type: none"> All CRC patients as part of initial diagnosis Does not require separate biomarker testing 	<p>Right-sided colon cancer is located in the cecum (caecum), ascending colon, hepatic flexure (right colic flexure) or transverse colon.</p> <p>Left-sided CRC is located in the splenic flexure (left colic flexure), descending colon, sigmoid colon, or rectum.</p>	<ul style="list-style-type: none"> Immunotherapy is effective in right-sided tumors. When added to traditional chemotherapy, bevacizumab is more effective than cetuximab in right-sided colon cancer. 	<ul style="list-style-type: none"> Adjuvant chemotherapy is effective in left-sided CRC. When added to traditional chemotherapy, cetuximab is more effective than bevacizumab in left-sided tumors.
PIK3CA	No standardized guidelines, patients should discuss with medical team	PIK3CA is a gene involved in controlling cell growth and migration. PIK3CA mutations may cause cancer as well as some rare diseases of abnormal growth.	For CRC without PIK3CA mutation (wild-type), treatment is guided by other patient and biomarker information.	<ul style="list-style-type: none"> Tumors with mutation in PIK3CA exon 20 are less responsive to EGFR inhibitor treatment. Colorectal cancer with PIK3CA mutation may have a good response to aspirin or other NSAIDs as neoadjuvant or adjuvant treatment, or as recurrence prevention.
TMB	No standardized guidelines, patients should discuss with medical team	TMB is tumor mutational burden, a measurement of how many genetic mutations are present in tumor cells in a specific amount of DNA (a megabase).	In colorectal cancer with TMB-Low, treatment is guided by other patient and biomarker information.	Immunotherapy is effective in CRC with TMB-High, even in some tumors with MSS.
NTRK FUSION	<ul style="list-style-type: none"> Patients with stage IV / metastatic CRC that is progressing on chemotherapy and has no KRAS, NRAS, or BRAF mutation No standardized guidelines for patients with stage IV / metastatic CRC with MSI-High, patients should discuss with medical team 	NTRK genes encode TRK proteins which are involved in control of cell growth and cell survival. When a type of mutation called NTRK gene fusion occurs, TRK fusion proteins are made. TRK fusion proteins can cause cancer by allowing uncontrolled cell growth and survival.	Tumors without NTRK fusion are treated based on other patient and biomarker information.	TRK inhibitors are used to treat CRC with NTRK fusion.
DPYD	<ul style="list-style-type: none"> All CRC patients experiencing severe toxic effects of 5-FU related chemotherapy (5-FU and its combinations, capecitabine and its combinations) No standardized guidelines for pre-treatment DPYD testing, patients should discuss with medical team 	DPYD is a treatment toxicity biomarker. DPYD is a gene encoding the enzyme DPD which is required to break down (metabolize) 5-FU related chemotherapy drugs. Mutations in DPYD may cause partial or complete DPD enzyme deficiency, leading to abnormal 5-FU metabolism and severe toxicity.	<ul style="list-style-type: none"> In patients with DPYD mutations causing partial DPD enzyme deficiency, doses of 5-FU related drugs may be reduced to lower the risk of severe toxic effects. In patients with DPYD mutations causing complete DPD enzyme deficiency, different drugs may be used to avoid 5-FU related chemotherapy. 	
UGT1A1	<ul style="list-style-type: none"> All CRC patients experiencing severe toxic effects of irinotecan chemotherapy No standardized guidelines for pre-treatment UGT1A1 testing, patients should discuss with medical team 	UGT1A1 is a treatment toxicity biomarker. It is a gene encoding the enzyme which is required to metabolize irinotecan. Mutations in UGT1A1 may cause decreased enzyme level or function, leading to abnormal irinotecan metabolism and severe toxicity.	In patients with UGT1A1 mutations, irinotecan dose may be reduced to lower the risk of severe toxic effects.	